Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Financials Strong, But Shareholder Calls For Sale Of Company

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO stepping down and no R&D leader on board, as officials evaluate pipeline.

You may also be interested in...



Endo Explains HealthTronics Acquisition to Wall Street: Relationships With Urologists Are Key

Endo's pending acquisition of HealthTronics and its settlement with Impax and Sandoz over generic Opana ER removes some near-term pressure on its shares.

Endo Explains HealthTronics Acquisition to Wall Street: Relationships With Urologists Are Key

Endo's pending acquisition of HealthTronics and its settlement with Impax and Sandoz over generic Opana ER removes some near-term pressure on its shares.

Endo Branches Out With $370M Indevus Acquisition

Re-submission of Nebido NDA in the wings, sales force will target general practitioners with urology, endocrinology drugs to general practitioners.

Related Content

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel